ENDPOINTS NEWS25m
GSK, iTeos re­ju­ve­nate strug­gling TIG­IT space with pos­i­tive Phase 2 Jem­per­li com­bo da­ta in lung can­cer
GSK and iTeos have unveiled positive mid-phase data for their PD-1 plus TIGIT doublet in certain lung cancer patients, ...
ENDPOINTS NEWS9h
SEC probe of Il­lu­mi­na’s Grail deal tar­gets sales fore­casts, sources say
The SEC’s investigation into the $8 billion deal between Grail and Illumina is examining sales forecasts made by Grail’s ...
ENDPOINTS NEWS10h
Ad­comm says In­ter­cep­t's rare liv­er dis­ease drug should not get full ap­proval
An FDA advisory committee recommended against full approval for Alfasigma and Intercept Pharmaceuticals’ rare liver disease ...
ENDPOINTS NEWS15h
Au­rinia re­struc­tures board, bring­ing in Kevin Tang and keep­ing CEO
Aurinia Pharmaceuticals offered an olive branch to a group of shareholders clamoring for change. It's shrinking its board by ...
ENDPOINTS NEWS12h
Af­ter a huge IPO and ac­qui­si­tion, Zymer­gen caps off bank­rupt­cy with $30M SEC penal­ty
The rise and fall of the short-lived biotech Zymergen has ended with a $30 million penalty from the SEC. Zymergen's rise ...
ENDPOINTS NEWS12h
Post-Hoc: Big promis­es built Mod­er­na. They might al­so be its un­do­ing
One of my distinct memories of the early pandemic was sitting in Moderna CEO Stéphane Bancel’s office in Cambridge, MA, as he ...
ENDPOINTS NEWS13h
Atea's poly­merase in­hibitor fails in late-stage Covid-19 treat­ment tri­al
Viral disease-focused biotech Atea Pharmaceuticals announced a late-stage trial failure for its nucleotide polymerase ...
ENDPOINTS NEWS18h
Doug Williams re­turns with a ‘FIT’ bet on CAR-Ts; Bio­gen ap­points Mene Pan­ga­los to board
Industry veteran Doug Williams is back with a new approach to CAR-T cell therapies that he expects to take into the clinic in ...
ENDPOINTS NEWS15h
On­line stim­u­lant pre­scrip­tions soared dur­ing Covid pan­dem­ic, study finds
Stimulants prescribed during telehealth visits rose dramatically during the Covid-19 pandemic, when relaxed US regulations ...
ENDPOINTS NEWS19h
Bicara, Zenas and MBX rekin­dle IPO mar­ket with rare Fri­day triple­head­er
After a sleepy few months, the biotech IPO market is waking up thanks to back-to-back-to-back listings. Oncology-focused ...
ENDPOINTS NEWS21h
Onc­ter­nal stops can­cer tri­als and be­gins search for fu­ture busi­ness op­tions
After disappointing efficacy data and a patient death, Oncternal Therapeutics is discontinuing two trials and looking for ...
ENDPOINTS NEWS22h
Roche’s Tecen­triq scores first US ap­proval for sub­cu­ta­neous PD-1
Just in time for the first day of ESMO, the FDA has approved its first-ever subcutaneous immunotherapy targeting PD-1 for ...